Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs

Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs

Published 3 weeks, 5 days ago
Description
In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundup covers Merck's $510 million collaboration with Protillion Biosciences and Jazz Pharmaceuticals' multi-program antibody discovery deal with AbCellera, and Jack McFeely argues that behavioral and engagement insights are the missing ingredient in patient support programs that struggle to sustain long-term persistence.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us